Celularity Inc (CELU) company profile
Close on Nov 17, 2026Market cap $18.53MP/E –Yield –
About Celularity
Pharmaceutical Preparations, SIC 2834
Celularity is a biotechnology company developing cell therapy products and biobanking services. The company specializes in cellular medicine, utilizing proprietary technology rights and cellular biological materials to develop therapeutic treatments. Alongside cell therapy research and development, it conducts biobanking operations and related service activities. The business also enters into intellectual property agreements, licensing arrangements, and research-oriented contracts. Its customer base includes commercial clients, institutional research partners, and healthcare organizations utilizing its biobanking services and cellular products.
The company operates office, laboratory, and manufacturing facilities located in Florham Park, New Jersey, where it conducts its core operational and scientific activities. Celularity maintains equipment and leasehold improvements at this facility to support its production and biobanking capacity. All primary operations, production capabilities, and corporate administration are concentrated at this single site in the United States, with corporate activities conducted from its New Jersey headquarters.
Summary of the business section of Celularity's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Celularity Inc
- Headquarters
- Florham Park, NJ
- Address
- 170 Park Ave 07932
- Phone
- (908) 768-2170
- Website
- celularity.com
- Employees
- 115, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- EisnerAmper LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- CELU
- Exchange
- Nasdaq
- IPO date
- May 21, 2019
- Shares outstanding
- 32M, Oct 19, 2026
- Public float
- $28.40M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Jul 30, 2024; 1-for-10 reverse, Feb 29, 2024; 3-for-1, Aug 19, 2021
- SEC CIK
- 1752828
- CUSIP
- 151190204
- ISIN
- US1511902041
- FIGI
- BBG00P2RTT34
- Share class FIGI
- BBG00P2RTT43
- EIN
- 83-1702591
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert J. Hariri | Chief Executive Officer, Director | 2,853,553 |
| Stephen Brigido | Pres., Functional Regeneration | 9,742 |
| John R. Haines | Senior Exec Vice President | 30,179 |
| Joseph DosSantos | Interim CFO | – |
| David C. Beers | Chief Financial Officer | 18,201 |
| Philip Alan Barach | Director | – |
| Geoffrey M.D. Ling | Director | 256,026 |
| Diane L. Parks | Director | 520,021 |
| Peter Diamandis | Director | 394,150 |
| Vincent LeVien | Director | 153,847 |
| Dean C. Kehler | Director | 797,858 |
| Richard J. Berman | Director | 67,416 |
Executive compensation, fiscal 2024
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Robert J. Hariri, M.D., Ph.D. Chief Executive Officer | $179.14K | $634.56K | $35.26K | $848.96K | -31% |
| John Haines Senior Executive Vice President, Chief Administrative Officer and Corporate Secretary | $434.38K | $46.66K | $35.97K | $517.01K | -37% |
| David Beers Chief Financial Officer(4) | $369.22K | $39.66K | $36.16K | $445.04K | -30% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- May 21, 2019
- Offer price
- $10.00
- Securities offered
- 25,000,000
- Gross proceeds
- $250.00M
- Exchange
- Nasdaq
- First trading day
- Jul 15, 2019
- First-day close
- $10.34+3.4%
- Lock-up ends (est.)
- Jan 11, 2020
“Each unit has an offering price of $10.00 and consists of one share of our Class A common stock and one -half of one redeemable warrant.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“had 115 full-time employees and 1 non-employee leased worker, most of whom are located at our Florham Park facility.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?